Last edition
News about "Glenmark Pharma launches generic Banzel tablets"
Glenmark Pharma launches generic Banzel tablets
Glenmark Pharmaceuticals has launched rufinamide tablets USP, 200 mg and 400 mg, a therapeutic equivalent of Banzel tablets, 200 mg and 400 mg of Eisai. Glenmark was one of the first ANDA applicants to submit a substantially complete ANDA for rufinamide tablets USP, 200 mg and 400 mg, with a paragraph IV certification and received final approval
Glenmark Pharma Launches Generic Banzel Tablets | 01/06/2021 | By Darshana | 149
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy